William Blair Reiterates Market Perform Rating on Allakos (ALLK), Believes lirentelimab May Ultimately Be Approved but Warns of Protracted Timelines and Additional Costs
Tweet Send to a Friend
William Blair analyst Tim Lugo reiterated a Market Perform rating on Allakos Inc. (NASDAQ: ALLK), following readout from the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
